PTC THERAPEUTICS, INC. (PTCT) Q3 2025 10-Q Quarterly Report
PTC THERAPEUTICS, INC. (PTCT) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 4, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
PTC THERAPEUTICS, INC. Q3 2025 10-Q Analysis
Risk Factors
- • New director/officer trading arrangements under Rule 10b5-1 adopted Sept 2025 for sales up to 259,346 shares, latest expiring March 2027
- • Updated insider trading compliance risk reflecting expanded use of Rule 10b5-1 plans to manage equity sales and tax obligations
PTC THERAPEUTICS, INC. Q3 2025 Quarterly FinancialsXBRL
Revenue
$211M
▲ +7.2% YoY▲ +18.0% QoQ
Net Income
$16M
▲ +114.9% YoY▲ +124.5% QoQ
Operating Margin
1.4%
▲ +2913bp YoY▲ +2097bp QoQ
Net Margin
7.5%
▲ +6173bp YoY▲ +4379bp QoQ
ROE
-10.2%
Total Assets
$2.6B
EPS (Diluted)
$0.16
▲ +111.5% YoY▲ +121.3% QoQ
Operating Cash Flow
-$66M
▲ +13.9% YoY▼ -13.7% QoQ
Source: XBRL data from PTC THERAPEUTICS, INC. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on PTC THERAPEUTICS, INC.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.